Citizens JMP Maintains Microbot Medical With Buy Rating, Adjusts Price Target
Citizens JMP analyst Daniel Stauder has maintained a 'Buy' rating on Microbot Medical (MBOT) while lowering the price target from $2.50 to $2.00.
Stocks · News reference
U.S. stocks fell Monday as tech slid and manufacturing sentiment weakened; oil, gold and silver also declined, while TELUS and H World surged.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citizens JMP analyst Daniel Stauder has maintained a 'Buy' rating on Microbot Medical (MBOT) while lowering the price target from $2.50 to $2.00.
22nd Century Group reported a 66% sequential increase in net revenue to $4.8 million and achieved a positive gross profit of $0.4 million for the third quarter of 2026.
Several financial institutions, including Wedbush, HC Wainwright, and RBC, updated their price targets and ratings for CG Oncology following recent clinical trial results.
iQIYI stock plummeted nearly 18% after the Chinese video streaming platform reported underwhelming Q3 2026 results, with revenue declining 10% year-over-year to 6 billion yuan and membership services revenue falling 6%. Despite narrowing net losses and claiming top content popularity, the company missed analyst estimates on both revenue and earnings per share, raising investor concerns about its strategic transformation efforts.
H World Group announced expanded asset-light operations and raised full-year revenue guidance in Q3 2026 earnings. The company is shifting toward managed franchise hotels to drive margin expansion while reducing capital requirements. Management highlighted supply chain optimization to protect franchisee margins, selective penetration of premium city hubs, and stronger-than-expected fourth-quarter travel demand across Chinese markets.
TELUS shares gain after confirming receipt of an unsolicited Québecor acquisition proposal, with an independent board committee reviewing regulatory and execution risks.